Deutsche Bank Cuts BASF to Hold on Evonik Deal Complexity — Not a Verdict on the Target

Deutsche Bank Research has trimmed its rating on BASF from "Buy" to "Hold" and lowered its price target from €60 to €53, citing the complexity and execution risks of a potential Evonik acquisition. The distinction matters for Evonik shareholders: the downgrade lands on the buyer, not the target, and should not be read as a sell signal on Evonik itself.

The analysts' move shifts attention from the headline price of any deal to whether the transaction can actually be pulled off. Their reservations center on the consequences an Evonik purchase could have for BASF, rather than on Evonik's own valuation.

A €24 Offer That Remains Unconfirmed

Behind the reassessment sits a Reuters report that BASF has raised its offer to €24 per Evonik share, valuing the bid at more than €11 billion. According to the report, BASF hopes the sweetened terms will bring Evonik to the negotiating table. The company had also attached commitments on jobs and production sites to the offer roughly a week earlier — pledges that concern how a combined group would be shaped, and are separate from the question of whether Evonik will engage in talks at all.

No confirmed agreement follows from any of this. Evonik declined to comment, and neither company has verified the reported offer. The Reuters terms therefore remain a media report rather than a jointly agreed transaction.

Evonik as Buyer, Too

Running in parallel is Evonik's own appetite for acquisitions. According to Handelsblatt, the specialty chemicals group has for some time been examining larger purchases in the US, with particular focus on Ashland. That review is still at an early stage and a deal is not certain. Reuters, citing Handelsblatt, also reported that investment banks have been mandated to scout for suitable takeover targets. Evonik declined to comment here as well.

Investors thus face two possible transaction directions — Evonik as acquirer or Evonik as target — and neither has been confirmed as a completed process.

Product Launches Carry On Regardless

The corporate newsflow has not paused for the deal speculation. Evonik has introduced Lypron, a rumen-stable lysine solution for amino acid supply in ruminants, presented on 19 October. Sipena is to manufacture Lypron exclusively for Evonik, giving the launch a clearly assigned production partner; the exclusivity applies to manufacturing for Evonik.

The offering is about supplying ruminants with the amino acid lysine, and Evonik describes the solution as rumen-stable. The launch demonstrates an expansion of the product range, but on its own says nothing about future earnings — what counts for investors is the eventual commercial weight of the product, not the announcement itself.

Other initiatives span different applications and different stages of maturity. On 20 October the company brought two VESTAKEEP PEEK grades to market for long-term dental prosthetics, the DC4760 and DC4780 variants, both designed for CAD/CAM processing. Separately, Evonik launched a chemical recycling initiative for polyurethane foam in Japan on 13 October alongside Toyotsu Chemiplas and Sanyo Chemical, aimed at recovering polyols and amines and testing a scalable recycling model.

Those projects are not equivalent evidence of future revenue: the new products are already introduced, while the recycling effort is a feasibility exercise.

Two Separate Questions for Investors

What emerges is a pair of distinct valuation questions. The takeover talks bear on a possible change in ownership structure, while Lypron, the dental resins and the Japanese recycling project concern the development of the product portfolio. Both deserve attention, but neither substitutes for a confirmed deal or for proof of commercial contribution. Above all, the latest analyst call underscores that any combination should not be judged on the offered price alone.